Genia Technologies

What Genia Technologies does

Genia Technologies is a privately held biotechnology company founded in 2009 and headquartered in Mountain View, California. The firm operates in the third-generation DNA sequencing technology market and its website domain (geniachip.com) implies a chip-based platform architecture for its sequencing offering. It maintains a workforce of 51–100 employees, indicative of an early-to-mid-stage life-sciences tools operation, and has raised at least one disclosed funding round of approximately $10.44 million dated 29 May 2013. No product portfolio details, pricing model, partnership agreements, named customers, or revenue figures are disclosed in the available sources, materially limiting visibility into the company's current commercial trajectory and stage.

Name

Genia Technologies

Legal name

Genia Technologies

Website

https://geniachip.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Genia Technologies is a privately held Mountain View, California biotechnology company founded in 2009 that operates in the third-generation DNA sequencing technology market with a chip-based platform implied by its geniachip.com domain and a workforce of 51–100 employees.

Ownership category

akta.pro rank

Product category

DNA Sequencing Instruments

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

Keywords

• DNA sequencing technology
• Third-generation sequencing
• Genomics platforms
• Nucleic acid analysis
• Biotechnology tools

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Genia Technologies operates in the third-generation DNA sequencing technology market. The company develops semiconductor chip-based platforms for nucleic acid sequencing, as indicated by its website domain (geniachip.com) and its positioning within the third-generation sequencing industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Third-generation DNA sequencing technology

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Illumina: Dominant short-read sequencing platform provider with the broadest installed base in genomics. Competes with Genia across research, clinical, and applied sequencing markets, and sets the cost/throughput benchmark against which third-generation platforms are measured.
• Roche: Strategic acquirer of Genia Technologies in 2014 and major diagnostics player with internal sequencing programs. Comparable as a partner/buyer for sequencing platforms and as a vertically integrated competitor in clinical sequencing.
• MGI Tech (BGI Group): Sequencing and life-sciences-tools provider offering DNBSEQ sequencing platforms. Competes in the broader sequencing market with Genia by offering cost-competitive short- and mid-range sequencing instruments globally.
• Thermo Fisher Scientific: Major life-sciences-tools and sequencing player (Ion Torrent). Competes in the sequencing instruments and reagents market and is a likely strategic acquirer or partner for niche sequencing platforms like Genia.

Emerging players

• Singular Genomics: Developer of next-generation sequencing instruments targeting benchtop and clinical research use. Comparable to Genia as a smaller sequencing platform challenger seeking to enter a market dominated by Illumina.
• Bionano Genomics: Developer of optical genome mapping systems for structural variation detection. Overlaps with Genia's third-generation genomics positioning as an alternative non-short-read platform for genome analysis.
• 10x Genomics: Provider of single-cell and spatial genomics tools that complement sequencing workflows. Comparable as a sequencing-adjacent platform company in the genomics tools ecosystem targeting similar research and translational customers.
• Stratos Genomics (acquired by Roche): Pre-acquisition developer of sequencing-by-expansion nanopore chemistry, also acquired by Roche. Directly comparable to Genia as a small third-generation sequencing company acquired for its differentiated chemistry.

Direct peers

• Pacific Biosciences: Developer of long-read, single-molecule real-time (SMRT) sequencing instruments. Directly competes with Genia in the third-generation sequencing category by offering an alternative long-read platform to research and clinical customers.
• Oxford Nanopore Technologies: Developer of nanopore-based sequencing platforms (MinION, PromethION, GridION). Most direct competitor to Genia, both targeting long-read, single-molecule sequencing via nanopore-based architectures.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• Xx.com/geniachip
• LinkedInlinkedin.com/company/genia-technologies

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genia Technologies